Medical
White House: Merck to help produce rival J&J's vaccine
WASHINGTON (AP) -- Drugmaker Merck & Co. will help produce rival Johnson & Johnson's newly approved coronavirus vaccine in an effort to expand supply Full article
-
US firm Moderna, Japan's Takeda to seek vaccine approval
(2021/3/2)
-
Many hospitals in Japan refusing COVID-19 patients with mental disabilities
(2021/3/2)
-
Japan receives 3rd batch of Pfizer COVID-19 vaccine
(2021/3/1)
-
Does the coronavirus vaccine hurt? Are there side effects? A Japanese doctor explains
(2021/2/28)
-
Experts notice pandemic's mental health toll on German youth
(2021/2/27)
-
US advisers endorse single-shot COVID-19 vaccine from J&J
(2021/2/27)
-
US approves Pfizer vaccine storage for 2 weeks at higher temperature
(2021/2/26)
-
Amid COVID-19 pandemic, flu has disappeared in the US
(2021/2/25)
-
Pfizer COVID-19 vaccine works well in big 'real world' test
(2021/2/25)
-
FDA says single-dose shot from J&J prevents severe COVID
(2021/2/25)
-
Takeda starts clinical trial of Novavax COVID-19 vaccine in Japan
(2021/2/24)
-
Tokyo reports 213 more coronavirus infections on Feb. 24
(2021/2/24)
-
Not to be sniffed at: Agony of post-COVID-19 loss of smell
(2021/2/23)
-
UK data: COVID-19 vaccines sharply cut hospitalizations
(2021/2/23)
-
What's safe after COVID-19 vaccination? Don't shed masks yet
(2021/2/21)
-
Japan minister warns of slower pace of COVID-19 vaccine shots for elderly
(2021/2/21)
-
Tokyo records 327 coronavirus infections on Feb. 20
(2021/2/20)
-
Study to predict serious COVID-19 cases from urine to go ahead in Japan with city's help
(2021/2/20)
-
Disease experts wary after discovery of virus mutation in Japan in Dec. 2020
(2021/2/20)
-
Osaka to ask for lifting of COVID-19 state of emergency at end of February
(2021/2/20)
Also in The Mainichi
- The Mainichi on social media
